Sanofi’s Lantus Had No Increased Cancer Risk in Studies

Sanofi’s best-selling diabetes treatment Lantus leads to no increased cancer risk, according to three studies that explored a possible link among patients after one to three years of treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.